Heat fixation inactivates viral and bacterial pathogens and is compatible with downstream MALDI mass spectrometry tissue imaging

Lisa H Cazares1,2,3*, Sean A Van Tongeren3, Julie Costantino3, Tara Kenny3, Nicole L Garza3, Ginger Donnelly3, Douglas Lane3, Rekha G Panchal3 and Sina Bavari3

Abstract

Background: Tissue samples should be fixed and permanently stabilized as soon as possible ex-vivo to avoid variations in proteomic content. Tissues collected from studies involving infectious microorganisms, must face the additional challenge of pathogen inactivation before downstream proteomic analysis can be safely performed. Heat fixation using the Denator Stabilizor System (Gothenburg, Sweden) utilizes conductive heating, under a mild vacuum, to rapidly eliminate enzymatic degradation in tissue samples. Although many studies have reported on the ability of this method to stop proteolytic degradation and other sample changes immediately and permanently, pathogen inactivation has not been studied.

Results: We examined the ability of the heat fixation workflow to inactivate bacterial and viral pathogens and the suitability of this tissue for Matrix Assisted Laser Desorption Ionization mass spectrometry imaging (MALDI-MSI). Mice were infected with viral or bacterial pathogens representing two strains of Venezuelan Equine Encephalitis virus (VEEV) and two strains of Burkholderia. Additionally, a tissue mimetic model was employed using Escherichia, Klebsiella and Acinetobacter isolates. Infected tissue samples harvested from each animal or mimetic model were sectioned in half. One half was heat fixed and the other remained untreated. Lysates from each sample were checked for organism viability by performing plaque (infectivity) assays or plating on nutrient agar for colony forming unit (CFU) calculation. Untreated infected control tissue demonstrated the presence of each viable pathogen by positive plaque or colony formation, whereas heat fixation resulted in complete inactivation of both the viral and bacterial pathogens. MALDI-MSI images produced from heat fixed tissue were reflective of molecular distributions within brain, spleen and lung tissue structures.

Conclusions: We conclude that heat fixation inactivates viral and bacterial pathogens and is compatible with proteomic analysis by MALDI-MSI. This treatment will enable the use of infected tissue from studies performed in bio-safety level 3 laboratories with VEEV and Burkholderia to be safely used for proteomic, small molecule drug detection, and imaging mass spectrometry analysis.

Keywords: Tissue fixation, Proteomics, Microbial inactivation, Matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), Tissue imaging
Background

Many challenges must be overcome for successful proteomic analysis in tissue samples. When sampling is performed in a manner optimal for experimental reproducibility and is a representative “snapshot” of the organisms living state, the highest sample quality for experimental analysis is achieved. Endogenous proteolytic activity begins immediately following disruption of oxygen and nutrients, and can continue during storage and sample processing [1]. Therefore, in order to obtain reliable and consistent results, tissue samples should be fixed and permanently stabilized as soon as possible ex-vivo to avoid significant variations in proteomic content throughout the experimental processes [2,3]. Tissue samples collected from animal studies involving infectious microorganisms must face an additional challenge of pathogen inactivation before downstream proteomic analysis can be safely performed in a routine laboratory environment (biosafety level 2). Therefore, biosampling procedures for infectious disease research must be carefully considered and optimized for both experimental integrity and safety.

Fixation of tissues can be accomplished by chemical or physical treatment. Physical methods include cryopreservation, heating, and micro-waving. The most common chemical fixation method is 10% neutral buffered formalin. This method is ideal for preserving cellular morphology and inactivates most pathogens, but produces extensive covalent crosslinking within proteins creating a challenge for subsequent proteomic and mass spectrometric analysis. These crosslinks can be partially reversed using antigen retrieval methods, to achieve maximum detection of proteins and peptides [4]. However, amino acids, carbohydrates, lipids, phosphates, proteins and ions, such as Cl(−) and K(+) have been shown to leach from tissue sections into the aqueous fixative medium, further creating sources of variability in molecular content [5]. Alcohol based fixatives can also preserve morphology and are more compatible with proteomic analysis [6], but suffer from the same potential problem of analyte leaching.

The most common physical method of tissue stabilization used in proteomic and mass spectrometry analysis is snap-freezing and cryo-preservation. Although this method can be performed very quickly after tissue harvest, enzymatic activity and degradation will begin again once the sample is thawed for processing or sectioning [7,8] and pathogens present in the tissue remain viable. Heat or microwave-irradiation-enhanced fixation was first demonstrated in 1970 [9] and can be performed to enhance and shorten the times for chemical fixation or be used alone. Recently a method of heat fixation utilizing a combination of heat and mild vacuum was reported to be a superior method for proteome stabilization in tissue when compared to snap-freezing [10]. Heat stabilization using the commercially available Denator Stabilizor System is compatible with major proteomic workflows and is beneficial in preserving peptides, proteins and their modifications in tissue samples [11-13]. In addition, heat stabilized tissues exhibit similar intensity distribution for marker ions as that seen in frozen tissue sections used for matrix assisted laser desorption ionization MALDI-MSI [8]. Although many studies have reported on the ability of this method to stop proteolytic degradation and other sample changes immediately and permanently, pathogen inactivation has not been studied.

MALDI-MSI is a powerful tool for the generation of multidimensional spatial expression maps of biomolecules directly from a thin tissue section. Cells, tissue sections or even whole body slices from small animals are deposited onto a conductive glass or metal plate and covered with matrix (usually a UV-absorbing weak organic acid dissolved in a volatile solvent). The analytes in the tissue are extracted by the solvent and co-crystallize with the matrix compound, which then facilitates the transfer of energy of the MALDI laser allowing for the desorption/ionization of the analyte molecules. Mass spectra can then be acquired across the tissue at defined geometrical coordinates resulting in ion intensity maps or images depicting the relative level of each detected analyte. MALDI ion sources are well suited to this application since they enable the ionization of diverse biomolecules, including peptides, proteins, oligonucleotides, sugars, lipids, and small molecule drugs when the appropriate matrix is employed [14-16].

Unlike traditional proteomic techniques where spatial information is lost due to extraction and purification, MALDI-MSI allows for the simultaneous detection of many analytes while maintaining their spatial distribution within a histologically defined tissue section. MALDI-MSI is generally a non-targeted approach and does not require any labels or specific probes. This makes MALDI-MSI an extremely useful biomarker discovery tool as it facilitates the collection of multiplexed data on the specific localization of molecular ions in tissue sections, and allows for the measurement and mapping of variations of these ions during development and disease progression or treatment. Therefore MALDI-MSI is valuable tool for monitoring the response to infection with highly pathogenic organisms for the discovery of biomarkers and therapeutic targets. This work describes the effectiveness of heat fixation using the Denator instrument for the inactivation of bacteria and viruses and the compatibility of this treatment with MALDI mass spectrometry imaging.

Results

Experimental design

The workflows used to evaluate the ability of heat fixation using the Denator Stabilizor T1 system to inactivate viral and bacterial pathogens in tissue samples are
Our experimental design included both an in-vivo infection model as well as a tissue mimetic model. Infected tissue samples were sectioned in half and heat fixed or left untreated, followed by pathogen viability assays. We chose to begin our investigation using a “custom” heat fixation method of 95°C for 30 seconds in the T1 Stabilizor instrument with the upper heater position at 90%. The temperature, heater position and stabilization time are settings that can be adjusted when selecting the “custom” method option. This custom setting is based on the default fresh structure preserving method of 90-95°C for 10–20 seconds for most tissues.

The structure preserving method evacuates the stabilizer card of air before heating takes place (to reduce the risk of oxidation), but does not compress the tissue with further vacuum. The time and temperature were chosen as starting points based on basic heat-inactivation data of bacteria and viruses in foods [17-19]. According to the manufacturer’s guidelines, the T1 Stabilizor instrument is compatible with tissue sample sizes up to 33 mm in diameter and 7 mm in height, and there is no lower limit for sample size. To determine the exact amount of energy required for complete heat fixation, the instrument uses algorithms which combine the details of the physical state (fresh or frozen) and the sample size (measured automatically by lasers).

Inactivation of viral pathogens in infected tissues
To evaluate if the heat fixation protocol inactivates viral pathogens from infected tissues, Venezuelan equine encephalitis virus (VEEV), an enveloped single stranded positive RNA virus classified in the Alphavirus genus and Togaviridae family was selected for testing. VEEV infection in mice begins with the lymphoid tissues, followed by viremia and penetration into and infection of the central nervous system [13]. In this study, BALB/c or C57BL/6 mice were infected (i.n. or s.c) with the vaccine or virulent strain of VEEV. Spleen and brain tissues harvested from infected mice were left untreated, or subjected to heat fixation and then lysates were prepared to determine viremia. As shown in Table 1, the presence of viable viral pathogen VEEV, (TC83 vaccine strain and virulent Trinidad donkey strain) was confirmed in the untreated mouse brain tissue lysates by positive plaque assays on Vero-76 cells. Viral titers from the TC83 VEEV infected untreated brain tissue lysates (100-120 mg) ranged from $2.5 \times 10^4$ to $5.5 \times 10^4$ pfu/ml. Higher titers were obtained from untreated brain tissue harvested from mice infected with the virulent VEEV strain, ranging from $9.9 \times 10^7$ to $4.2 \times 10^8$. Lysates derived from the untreated spleen of mice infected with the virulent strain of VEEV exhibited titers of $6.5 \times 10^5$-$2.5 \times 10^6$, however, no virus was recovered from the spleen tissue lysates derived from the TC83 infected mice. This is not surprising since mice challenged with live attenuated vaccine strain TC83, develop lower virus titers in the blood and brain and do not exhibit the histo-pathological lesions that occur in the spleen, lymph nodes, and brain tissue of mice infected with the virulent strain [20]. Most importantly, the heat fixed brain and spleen tissue samples produced no positive plaques indicating that both strains of VEEV were completely inactivated by the treatment.

Inactivation of bacterial pathogens in infected tissues
To evaluate the ability of the heat fixation method to inactivate bacterial pathogens, the Gram negative bacilli Cuprodon thailandensis, an avirulent strain, and Burkholderia
mallei, a virulent strain that causes glanders disease, were selected for study. The initial stage of infection in BALB/C mice with both of these strains results in the localization of the pathogen in the upper and lower sections of the respiratory tract and transportation of bacteria within alveolar macrophages to regional lymph nodes [21]. Mice were infected with either B. thailandensis or B. mallei and after 4 days, spleen and lung tissues were harvested and subjected to either no treatment or heat fixation. Tissue lysates were prepared for a bacterial viability assay. As shown in Table 2, lysates from the untreated lung tissue harvested from mice infected with B. thailandensis or B. mallei exhibited colony counts in excess of $10^5$ CFU/ml, indicating that both bacteria invaded the lungs of all infected mice. Viable bacterial counts in the untreated spleen of B. thailandensis infected mice ranged from $7.0-7.6 \times 10^4$ CFU/ml. Conversely, there were no viable bacteria detected in heat-fixed lung or spleen tissue, indicating complete inactivation. Spleen tissue was not harvested from the B. mallei infected mice due to the fact that bacterial numbers are consistently higher in the lungs than in other tissues when an aerosol or intranasal infection method is used [21].

In an effort to limit the use of animals for this study, we employed a tissue mimetic model to further investigate the ability of heat fixation to inactivate Gram negative bacteria from 3 families (Enterobacteriaceae, Moraxellaceae, and Burkholderiaceae), and 4 different genera: Escherichia coli (3 strains), Klebsiella pneumoniae, Acinetobacter baumannii and Burkholderia thailandensis. Whole kidneys harvested from uninfected control animals were inoculated with the bacterial isolates (one isolate for each kidney) and incubated at $37^\circ$C for 1 hour. After incubation, the kidneys were sectioned in half and one half was heat fixed and the other half was left untreated. Lysates of each tissue were made as previously described and viable bacterial counts were determined by plating serial dilutions on Lysogeny broth (LB) agar. As shown in Table 3, viable

Table 1 Viable virus determination from untreated and heat fixed VEEV (vaccine strain and virulent strain) infected tissue

| Pathogen                  | Tissue | Weight (mg) | Treatment | Dilution and plaque count | Average titer (pfu/ml) |
|---------------------------|--------|-------------|-----------|---------------------------|------------------------|
| VEE (TC83) vaccine strain | brain  | 100         | none      | $10^{-1}$ 21 3 0 0 0     | $2.5E + 04$           |
|                           |        | 120         | none      | $10^{-2}$ 30 8 0 0 0     | $5.5E + 04$           |
|                           |        | 140         | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           | spleen | 47          | none      | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 52          | none      | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 55          | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 50          | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
| VEE (Trinidad donkey) virulent strain | brain  | 210         | none      | TNCT TNCT TNCT TNCT TNCT | $4.2E + 08$           |
|                           |        | 240         | none      | TNCT TNCT TNCT TNCT 58 14 | $9.9E + 07$           |
|                           |        | 220         | none      | TNCT TNCT TNCT TNCT TNCT 57 37 | $3.7E + 08$           |
|                           |        | 190         | none      | TNCT TNCT TNCT TNCT TNCT 34 | $3.4E + 08$           |
|                           |        | 190         | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 180         | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 260         | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 210         | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           | spleen | 60          | none      | TNCT TNCT 42 7 0 0 0     | $2.5E + 06$           |
|                           |        | 50          | none      | 45 13 0 0 0 0 0 0 8.8E + 03 |
|                           |        | 50          | none      | 39 11 0 0 0 0 0 0 7.5E + 03 |
|                           |        | 70          | none      | 38 9 0 0 0 0 0 0 6.5E + 03 |
|                           |        | 50          | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 60          | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 50          | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |
|                           |        | 70          | HF        | 0 0 0 0 0 0 0 0 0 0 0     | $0.0E + 00$           |

TNTC = too numerous to count, HF = Heat fixed.
bacterial colonies were detected for each isolate tested in all the untreated kidney tissue (>10^3 CFU/ml). No viable bacteria was detected in the kidney tissue which was heat fixed at 95°C for 30 seconds, indicating complete inactivation of all bacterial isolates present in the tissue mimetic.

**Evaluation of heat fixed tissue for compatibility with MALDI-MSI**

To evaluate the tissues for gross morphology and MALDI-MSI, duplicate samples were heat-fixed and prepared for sectioning by embedding in OCT and freezing at ~80°C. One untreated brain tissue and one untreated lung tissue were also embedded in OCT. Cryo-sectioning was performed and 10 μm sections were placed on ITO coated slides for MALDI-MSI. Serial sections were H&E stained to evaluate tissue morphology after heat fixation (95°C for 30 s). Upon gross examination, heat fixation increased the rigidity of the tissue samples and the tissue appeared darker and slightly reduced in overall size. Additionally, the tissue was more prone to fracturing during cryo-sectioning as compared to snap-frozen tissue. As seen in Figure 2, the overall tissue structures are intact, but morphology changes were observed at the cellular level. Heat-fixed tissue displayed morphological changes similar to those observed in most snap-frozen sections. The expansion of water in the tissue upon freezing causes a consistent distortion, creating a "swiss cheese" effect. Some of these holes may be attributed to ice crystal formation, although the snap-frozen brain, embedded using the same method of immersion in pre-chilled isopentane bath cooled with dry ice, did not display these holes. It has been proposed that these small holes may be caused by the formation of steam pockets within the tissue during the rapid heating process [8].

The preservation of distinct morphological structures in the tissue is apparent in the MALDI-MSI images produced from heat fixed brain, spleen and lung tissue. As seen in Figure 3A, heat fixed spleen tissue exhibited differential expression of a peak at m/z 8426 ± 46 localized to the areas of periarteriolar lymphocyte sheath (PALS), and heat fixed lung tissue displayed a peak at m/z 12167 ± 67 unique to the primary bronchus. The large holes seen in the serial H&E sections are not visible in the MALDI-MSI images of the lung and spleen. This is most likely due to analyte diffusion into these areas during tissue washing or matrix application. Brain tissue structure is also preserved and displays ions with differential expression in 2 regions of the midbrain (Figure 3B inset). This is an indication that the changes to the fine structure observed in the H&E of the heat fixed tissue did not affect our ability to detect differential expression of peptides and proteins by MALDI-MSI, producing images reflective of the underlying morphology. In addition, as shown in Figure 3B, the spectral profile of the heat fixed brain tissue exhibits increased intensity for peaks above 12 kDa as compared to frozen spectra from the same brain region. Conversely spectra from untreated tissue displayed a larger number of low molecular weight ions, consistent with protein degradation.

In order to evaluate the effects of heat fixation with pathogen inactivation on smaller tissue analytes, MALDI

---

**Table 2 Viable bacteria determination from untreated and heat-fixed *Burkholderia* infected tissue**

| Pathogen                  | Tissue | Weight (mg) | Treatment | cfu for 10^-1 | Average cfu/ml |
|---------------------------|--------|-------------|-----------|---------------|----------------|
| *B. thailandensis*        | lung   | 40          | none      | 1000+         | >1 x 10^5      |
|                           |        | 52          | none      | 1000+         | >1 x 10^5      |
|                           |        | 40          | none      | 1000+         | >1 x 10^5      |
|                           |        | 56          | HF        | 0             | 0.00           |
|                           |        | 48          | HF        | 0             | 0.00           |
|                           |        | 34          | HF        | 0             | 0.00           |
| spleen                    |        | 61          | none      | 70            | 7.0 x 10^4     |
|                           |        | 64          | none      | 71            | 7.1 x 10^4     |
|                           |        | 71          | none      | 76            | 7.6 x 10^4     |
|                           |        | 57          | HF        | 0             | 0.00           |
|                           |        | 45          | HF        | 0             | 0.00           |
|                           |        | 65          | HF        | 0             | 0.00           |
| *B. mallei*               | lung   | ND          | none      | 1000+         | >1 x 10^5      |
|                           |        | ND          | none      | 1000+         | >1 x 10^5      |
|                           |        | ND          | none      | 1000+         | >1 x 10^5      |
|                           |        | ND          | HF        | 0             | 0.00           |
|                           |        | ND          | HF        | 0             | 0.00           |
|                           |        | ND          | HF        | 0             | 0.00           |

HF = Heat fixed, ND=not determined.

---

**Table 3 Bacterial viability determination from untreated and heat-fixed kidney tissue obtained from a tissue mimic model**

| Bacterial isolate          | Treatment       | 1:10  | 1:100 | 1:1000 | cfu/ml |
|----------------------------|-----------------|-------|-------|--------|--------|
| *E. coli* Top10            | none            | TNTC  | 1000+ | 1000+  | >10^5  |
| *E. coli* pGSV3-GmR        | none            | TNTC  | 1000+ | 1000+  | >10^5  |
| *E. coli* pAM17-KanR       | none            | TNTC  | 1000+ | 1000+  | >10^5  |
| *Klebsiella pneumoniae*    | none            | TNTC  | 1000+ | 1000+  | >10^5  |
| *Burkholderia thailandensis* | none        | TNTC  | 1000+ | 1000+  | >10^5  |
| *Acinetobacter baumani*    | none            | TNTC  | 1000+ | 1000+  | >10^5  |
| Control (no bacteria)      | none            | 0     | 0     | 0      | 0      |
| *E. coli* Top10            | heat fixed      | 0     | 0     | 0      | 0      |
| *E. coli* pGSV3-GmR        | heat fixed      | 0     | 0     | 0      | 0      |
| *E. coli* pAM17-KanR       | heat fixed      | 0     | 0     | 0      | 0      |
| *Klebsiella pneumoniae*    | heat fixed      | 0     | 0     | 0      | 0      |
| *Burkholderia thailandensis* | heat fixed      | 0     | 0     | 0      | 0      |
| *Acinetobacter baumani*    | heat fixed      | 0     | 0     | 0      | 0      |
| Control (no bacteria)      | heat fixed      | 0     | 0     | 0      | 0      |

TNTC = too numerous to count, HF = Heat fixed.
tissue imaging for lipids was performed on snap frozen and heat fixed brain sections. For this analysis an effort was made to section and image similar brain regions for better comparison of brain structures and the molecules detected. Horizontal sections of mouse brain where made through regions of the cerebrum and cerebellum, sprayed with DHB matrix and subjected to MALDI-MSI in reflector negative ion mode. As shown in Figure 3C, the average total spectra exported from the compiled MALDI-MSI data set for heat fixed and snap frozen mouse brain both display numerous peaks representing lipid ions in the m/z 700–950 region. Based on previous published analysis of lipids mapped to mouse brain, the major classes of lipids visible in heat fixed and snap frozen brain tissue are glycerophospholipids such as phosphatidylinositol (PI), phosphatidylethanolamine (PE) and phosphatidylserine (PS), and phosphosphingolipids such as sphingomyelin [22]. These lipid classes are frequently observed in brain tissue via MALDI-MS in negative ion mode [23,24]. MALDI-MSI ion images produced for two ions at m/z 715.5 and m/z 885.6 show differential expression within different brain regions, but the pattern of expression is almost identical in the heat fixed and frozen brain sections. The ion at m/z 885.6 is present only in the inferior and superior colliculus, and corresponds well to the deprotonated form of phosphoinositol (38:4) which has a mass of 886.56 and is frequently observed in MALDI-MSI lipid analysis of mouse and rat brain tissue [23]. The ion at m/z 715.5 is primarily located in the cerebral cortex and has a similar mass to deprotonated PE-Cer/Sphingomyelin (C35:1 m/z 716.58). The similarity of the acquired spectra and images produced from heat fixed and frozen brain tissue indicates that the lipid profile is preserved after the pathogen inactivation/heat fixation process.

**Discussion**

Proteomic analysis of tissue infected with bacterial or viral pathogens poses a dual challenge since both microbial inactivation and tissue stabilization must be considered. The use of fresh or frozen tissue samples is not an option for studies involving BSL-3 or BSL-4 level pathogens. Although formalin fixation of such tissues is performed, the prolonged fixation protocols (14–30 days) often dictated to ensure pathogen inactivation, render tissue virtually unusable for proteomic analysis due to extensive protein crosslinking. Heat-fixation using the Denator Stabilisor T1 instrument has been successfully applied to many proteomic workflows using tissue, including 2D electrophoresis [25], analysis of protein phosphorylation and other post-translational modifications [11,26], but the use of heat fixation for microbial inactivation has not been studied previously. Recent reports by Goodwin et al. [8,27,28] have determined that heat fixation, using the basic structure preserving protocol, is compatible with MALDI-MSI, and produces protein profiles and ion images similar to, but more stable over time than fresh frozen. Since our method of pathogen inactivation requires a longer heat-fixation time, we sought to ensure that this treatment did not impair tissue morphology and structure to a degree that would preclude its use for MALDI-MSI.

Our data indicate that heat fixation at 95°C for 30 seconds is adequate for the inactivation of a + ssRNA enveloped virus in infected tissue samples. Initially, we chose as our guideline the temperatures and times used to inactivate viruses and bacteria in animal meat (pork beef or chicken) or shellfish [18,19,29,30]. Complete inactivation of the Hepatitis A virus, (a non-enveloped + ssRNA virus) in shellfish can be achieved by heat treatment at 90°C for 1.5 minutes [18]. In pilot experiments, we chose time points of 30 sec.-1.5 min. at 95°C for heat fixation of VEEV (TC83) infected tissue (data not shown). However, since VEEV was successfully inactivated at 30s, we did not perform the longer fixation times in subsequent studies.

It is often assumed that small non-enveloped viruses are among the most stable viruses and that viral sensitivity to heat increases with size and the presence of a viral envelope. However, a recent study measuring the thermal stability of many different viruses in a variety of
Figure 3 (See legend on next page.)
matrices, did not find a relation between viral structure and thermal stability [31]. This study reported that most viruses were inactivated by heating to 73°C for 3 minutes in a liquid matrix and that virus infectivity loss occurs much more rapidly than does loss of amplifiable viral RNA or DNA. Indeed, Baert et al. reported that RT-PCR determination for the presence of mouse norovirus (MNV) did not correlate with the infectivity of virus particles after heat treatment [32]. Therefore, the loss of virus infectivity observed after heat treatment is most likely due to denaturation of the capsid protein. Further studies are necessary to determine the heat fixation parameters required for the inactivation of viruses from non-enveloped and “naked” virus types.

The method of heat fixation using the Denator T1 Stabilizer was adequate for the inactivation of Gram negative bacteria from 3 families (Enterobacteriaceae, Moraxellaceae, and Burkholderiaceae). It is likely that this treatment will inactivate most other gram negative bacterial isolates. Since the cell wall of Gram-negative organisms is much more complex than the cell wall of Gram-positive bacteria, our heat fixation parameters may be adequate for inactivation, with the exception of spores. Further studies using tissue infected with Gram positive bacteria are necessary to ensure safe handling after heat fixation.

Our MALDI-MSI images are reflective of molecular abundances and distributions within tissue structures in heat fixed brain, spleen and lung tissue. By embedding heat fixed tissue in OCT, cryo-sections can be obtained although the tissue is prone to fracturing. To alleviate this problem, fragile heat-fixed tissue has been cryo-sectioned with the assistance of carbon conductive tape, in preparation for MALDI-MSI [27]. The tissue morphology we observed after heat fixation is of adequate integrity to obtain MALDI-MSI images and spectra of good quality, however, changes to cellular fine structure were observed. The source of these tissue changes and/or artifacts has not been determined. The protein/peptide spectra produced from heat-fixed brain tissue displays many common ions with spectra from fresh-frozen tissue, although there were fewer low molecular weight ions visible in the average spectra exported from heat fixed brain tissue. Since a direct comparison of heat-fixed to frozen tissue profiles was not the goal of this study, an in-depth analysis of the spectral profiles was not performed. However, this observation is consistent with a recent study by Stingl et al., which reported fewer ex-vivo formed peptides in rodent brain tissue heat-fixed samples as compared to fresh frozen material [3].

MALDI-MSI has been widely used to analyze a variety of lipids in tissue sections [33-36]. Due to the high content and diversity of lipids in the central nervous system, brain tissue often serves as a model for MALDI-MSI method development. We therefore sought to determine the impact heat fixation had on lipid detection within mouse brain sections using MALDI-MSI. Brain tissue heat fixed for pathogen inactivation produced a pattern of lipid expression similar to snap frozen brain tissue indicating that the treatment did not change the lipid analyte content or distribution. Although there are no published studies which directly compare the lipid content of heat fixed and snap frozen tissues, recent studies have highlighted the importance of careful pre-analytical sample handling of tissue for lipid analysis as many lipids are unstable, prone to oxidation and breakdown by tissue lipases [37,38]. In one such study, heat fixation of brain tissue successfully prevented the post-sampling breakdown of lipids and the release of free fatty acids through heat inactivation of lipases [37]. In this respect, heat fixation using the Denator T1 stabilizer is a valuable tool for the preservation of the spatial distribution of lipids in tissues providing a representative “snapshot” of an organisms living state.
Conclusions
Heat fixation of 95°C for 30 seconds using the Denator T1 Stabilizor can be used for the inactivation of ssRNA (+) enveloped viruses and Gram negative bacteria and is compatible with MALDI-MSI for protein/peptide and lipid analysis. To our knowledge this is the first report of the ability of this treatment to inactivate microbes. Further studies will be focused on the effectiveness of this treatment for the inactivation of other pathogenic viruses and bacteria. This tissue stabilization method is simple and rapid, and will facilitate the use of infected tissue samples from animal or human studies for downstream proteomic, small molecule drug detection, and imaging mass spectrometry analysis.

Methods
Animal Experiments and tissue mimetic model
Female BALB/c or C57BL/6 mice obtained from Charles River Laboratory (Frederick, MD) were infected intranasally (i.n.) or sub-cutaneously (s.c) with the viral pathogen Venezuelan equine encephalitis virus (VEEV), or the bacterial pathogens, Burkholderia thailandensis or Burkholderia mallei. Four mice total were infected with the vaccine strain of VEEV (TC83, i.n., 10^6 pfu) or the virulent strain (Trinidad donkey: s.c., 10^3 pfu). Four mice were infected with B.thailandensis and 3 mice were infected with B.mallei. (i.n., 10^5 CFU). Additional inactivation studies were conducted using a tissue mimetic model. Briefly, kidneys were harvested from uninfected control animals used in the above studies and injected with one of the following bacterial isolates: E.coli (Top10, PGSV3-GmR pAM17-KanR), Klebsiella pneumonia, Acinetobacter baumannii or Burkholderia thailandensis, ex-vivo using a 1 ml tuberculin syringe loaded with a 100 μl suspension of 3 × 10^8 CFU/ml in PBS. One kidney was used for each bacterial isolate and one was used as an uninfected control.

Research was conducted under an IACUC approved protocol in compliance with the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conducted is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011.

Heat fixation
After active infection was established (4–5 days), the primary target organs for each pathogen were harvested: brain and spleen from VEEV- infected mice and lung and spleen from Burkholderia- infected animals. Brain and spleen were removed aseptically from each of the 4 mice infected with the vaccine strain of VEEV. Two of the tissue sets (brain and spleen) were quickly divided in half. One half was heat fixed and the other half was left untreated. These tissues were used for viral titer determination. The brain and spleen from the other two animals were heat fixed or snap frozen whole and were used for MALDI-MSI studies (see below). All tissues recovered from the mice infected with the virulent strain of VEEV were sectioned in half and used to make lysates for viral titer determination.

Lung and spleen harvested from 4 mice infected with B. thailandensis were also divided in half, with one half heat fixed and the other untreated. Three paired tissue sets (heat-fixed and untreated) were used for CFU determination and the last pair was processed for MALDI-MSI. For the tissue mimetic samples, kidneys harvested from mice were injected with one of six different bacterial isolates and incubated at 37°C for 1 hour. The tissues were divided in half. One half was heat fixed and the other half was left untreated.

Heat fixation was performed using the T1 Stabilizor (Denator, Gothenburg, Sweden). Briefly, tissues were placed in the stabilizer card (Denator) according to the manufacturer’s guidelines and the instrument was programmed to a “custom” setting of 95°C for 30 seconds (based on the “fresh structure preserving” method) with a heater position of 90%. The temperature, upper heater position and stabilization time are settings that can be adjusted when selecting the “custom” method option in the instrument. Tissue weights ranged from 34-260 mg before heat fixation.

Viable pathogen determination
Tissue samples were weighed and lysates made with a Precellys®24-Dual (Bertin Technologies, Rockville, MD USA) bead beater device in 500 μl of RPMI-1640 media with 10% fetal bovine serum (FBS) for virus infected tissue or water for bacterial infected tissue. For the determination of viable virus from brain and spleen tissue, lysates were used in a plaque assay using Vero-76 cells. Cells were plated in 6-well plates 24 to 48 hours prior to use in assay, and plates were carried into the BSL-3 lab. SeaKem ME Agarose (Lonza, Rockland, MD, USA) was prepared for overlays by mixing an appropriate amount of agarose with an appropriate amount of Basal Medium Eagle (BME) to achieve the desired concentration (i.e., 1 g of agarose mixed with 100 ml of BME to achieve 1% agarose concentration). Agarose was melted by microwave in BSL-3 prior to use. Samples were diluted in 1× MEM (minimal essential media), supplemented with 10% FBS (vol/vol), in a 10-fold dilution scheme according to the experimental design. The culture medium in the 6-well plate was then removed by swift decanting and various dilutions of the virus inocula were added to duplicate or replicate wells in volumes of 100 μl. Inoculum fluid was distributed
by manual gentle rocking. The plates were incubated at 37°C with 5% CO2 for about 1 hour. Without removal of the inoculum or washing the virus off of the monolayer, a primary liquid overlay containing a 1:1 ratio of 2× BME medium (supplemented with 10% FBS) equilibrated to 42°C and 1% melted agarose was overlaid in 2 ml aliquots onto the inoculated monolayer and allowed to solidify. Plates were incubated for approximately 24 hours and stained with 2 ml of secondary overlay which consisted of 1:1 volume ratio of 2× BME media + 10% FBS: 1% agarose, and the combined volumes were supplemented with 5% neutral red. Plaques were counted and recorded 24 hours post-staining.

For determination of viable bacteria, lysates from lung, spleen and the kidney mimetic model were tested by plating 100 μl of serial dilutions on LB or blood agar in duplicate and incubating for 48 h at 37°C. Bacterial load was calculated as an average of the countable colonies seen in each dilution.

MALDI-MSI-tissue preparation and matrix application
Parallel tissue samples (heat-fixed and untreated) from the mouse infection studies were embedded in OCT (optimal cutting temperature cryo-compound), (Sakura Finetek, Torrence, CA, USA) freezing medium, immersed in a pre-chilled isopentane bath cooled with dry ice to freeze, and then stored frozen at −80°C. Sections (10 μm) were made with a Leica cryostat (Leica CM1900 Leica Microsystems Inc. Buffalo Grove, IL, USA) and were placed on ITO coated slides (Bruker Daltonics, Billerica, MA, USA) for MALDI-MSI. Serial sections (5 μm) were hematoxylin and eosin (H&E) stained for morphological analysis. After sectioning, the MALDI-MSI slides were rinsed in 70% ethanol for 30 seconds, followed by 95% ethanol for 30 seconds and a brief water wash to remove the OCT compound. Finally, the slides were again rinsed in 70% ethanol and 95% ethanol to dehydrate the tissue. After 1 hour in a dessicator, slides were sprayed with sinapinic acid (SA: 10 mg/ml in 50% acetonitrile, 1% TFA) for protein detection or 2,5-dihydroxybenzoic acid (DHB: 30 mg/ml in 50% methanol, 1% TFA) for lipid detection, in an ImagePrep spraying device (Bruker Daltonics) using the manufacturer’s recommended method for SA or DHB application respectively. After matrix application, the slides were stored in a dessicator under vacuum for 1 hour before MALDI-MSI.

MALDI-MSI-instrument settings and data visualization
MALDI-MSI was performed on an AutoFlex III (Bruker Daltonics) equipped with a SmartBeam™ laser (Nd: YAG, 355 nm). For protein detection the instrument was operated in linear positive–ion mode over a mass range of 2-20 kDa, with a raster width of 100 μm and a laser focal laser spot size of 20 μm. Five hundred laser shots were summed at each location in a random walk pattern that collects 100 shot increments at five random areas within each location. The extraction voltage was 19.94 kV, the acceleration voltage was 18.64 kV, and the lens voltage was 6.98 kV. Calibration was performed externally using protein standard mix 1(Bruker Daltonics). For lipid detection, the instrument was operated in reflector mode with negative polarity over a mass range of 100–1800 Da with a raster width of 100 μm and 20 μm laser spot size, summing 500 shots at each location with an acceleration potential of 20.97 kV. Spectra were calibrated internally using the DHB matrix peaks of m/z 153.02: [M-H]−, and m/z 307.04: [2M-H]−. All MALDI mass spectrometry data was processed and images were viewed using Flex Imaging 4.0 (Bruker Daltonics). Peaks were selected with a mass window 0.4% for proteins and 0.1% for lipids and minimum intensity of 1%. All data was normalized to total ion current.

Abbreviations
MALDI-MSI: Matrix assisted laser desorption ionization mass spectrometry imaging; VEEV: Venezuelan equine encephalitis virus; PFU: Plaque forming unit; CFU: Colony forming unit; OCT: Optimum cutting temperature; ITO: Indium tin oxide; BSL-3/4: Biosafety laboratory level 3 or 4.

Competing interests
The authors declare that they have no competing interests.

Author’s contributions
LHC conceived of the study, coordinated the efforts, participated in all the BLS-2 work, performed the MALDI-MSI and wrote the draft of the manuscript, SVT participated in the VEEV (vaccine strain), and B. thailandensis mouse work, JC performed the TC83 tissue processing and plaque assay, TK participated in the work using B. thailandensis, and edited the draft; NLG and GD performed the VEEV (viral strain) study in BSL-3. DL performed the B Daley BSL-3 study, RGP contributed to study design and helped to draft the manuscript draft, SB contributed to study design and coordinated the research efforts. All authors have read and approved the manuscript.

Acknowledgements
This research was funded by JSTO under USAMRIID project number 1323839. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the US Army. This work was sponsored by the U.S. Army Medical Research and Materiel Command. The U.S. Army Medical Research Acquisition Activity (Fort Detrick, MD) is the awarding and administering acquisition office. This document was prepared as an account of work sponsored by an agency of the U.S. Government. Neither the U.S. Government nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the U.S. Government. The views and opinions of authors expressed herein do not necessarily state or reflect those of the U.S. Government and shall not be used for advertising or product endorsement purposes.

Author details
1Henry M. Jackson Foundation, Maryland, USA. 2DoD Biotechnology High Performance Computing Software Applications Institute (BHSIA/TATRC), Frederick, Maryland, USA. 3Division of Molecular and Translational Sciences, US Army Medical Research Institute for Infectious Diseases (USAMRIID) Fort Detrick, Maryland, USA.
Received: 11 August 2014 Accepted: 23 April 2015
Published online: 13 May 2015

References

1. Skold K, Alm H, Scholtz B. The impact of biosampling procedures on molecular data interpretation. Molecular & cellular proteomics : MCP. 2013;12(6):498–501.

2. Jones RJ, Boyce T, Fennell M, Jacobs V, Pinto F, Duffield E, et al. The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemother Pharmacol. 2008;61(1):23–32.

3. Stingl C, Söderquist M, Karlsson O, Börén M, Luider TM. Uncovering effects of ex-vivo protease activity during proteomics and peptidomics sample extraction in rat brain tissue by oxygen-18 labelling. J Proteome Res. 2014;13(6):2807–17.

4. Ronci M, Bonanno E, Colantoni A, Pieroni L, Di Ilio C, Spagnoli LG, et al. Protein unlocking procedures of formalin-fixed paraffin-embedded tissues: application to MALDI-TOF imaging MS investigations. Proteomics. 2008;8(18):3702–14.

5. Hackett MJ, McQuillan JA, El-Assaad F, Aitken JB, Levina A, Cohen DD, et al. Chemical alterations to murine brain tissue induced by formalin fixation: implications for biopspectroscopic imaging and mapping studies of disease pathology. Analyst. 2011;136(14):2941–52.

6. Chaurand P, Latham JC, Lane KB, Mobley JA, Polosukhin VV, Wirth PS, et al. Imaging mass spectrometry of intact proteins from alcohol-preserved tissue specimens: bypassing formalin fixation. J Proteome Res. 2008;7(8):5343–55.

7. Goodwin RJ, Dungworth JC, Cobb SR, Pitt AR. Time-dependent evolution of tissue markers by MALDI-MS imaging. Proteomics. 2008;8(18):3801–8.

8. Goodwin RJ, Lang AM, Allingham H, Börén M, Pitt AR. Stopping the clock on proteomic degradation by heat treatment at the point of tissue excision. Proteomics. 2010;10(9):1751–61.

9. Mayers CP. Histological fixation by microwave heating. J Clin Pathol. 1970;23(3):273–5.

10. Svensson M, Börén M, Skold K, Fälth M, Stigren B, Andersson M, et al. Heat stabilization of the tissue proteome: a new technology for improved proteomics. J Proteome Res. 2009;8(2):974–81.

11. Ahmed MM, Gardiner KJ. Preserving protein profiles in tissue samples: differing outcomes with and without heat stabilization. J Neurosci Methods. 2011;194(1):99–106.

12. Kultima K, Skold K, Börén M. Biomarkers of disease and post-mortem changes - Heat stabilization, a necessary tool for measurement of protein regulation. J Proteomics. 2011;75(1):145–59.

13. Sturm RM, Greer T, Woodards N, Germerline E, Li L. Mass spectrometric evaluation of neuropodictomic profiles upon heat stabilization treatment of neuroendocrine tissues in crustaceans. J Proteome Res. 2013;12(2):743–52.

14. Vestal ML. Modern MALDI time-of-flight mass spectrometry. Journal of mass spectrometry : JMS. 2009;44(3):303–17.

15. Chaurand P, Schriver KE, Caprioli RM. Instrument design and characterization for high resolution MALDI-MSI imaging of tissue sections. Journal of mass spectrometry : JMS. 2007;42(4):476–89.

16. Rohner TC, Staab D, Stocekli M. MALDI mass spectrometric imaging of biological tissue sections. Mech Ageing Dev. 2005;126(1):177–85.

17. Croci L, Ciccozi M, De Medici D, Di Pasquale S, Fiore A, Mele A, et al. Inactivation of hepatitis A virus in heat-treated mussels. J Appl Microbiol. 1999;87(6):884–8.

18. Sow H, Desbiens M, Morales-Rayas R, Ngaozo SE, Jean J. Heat inactivation of hepatitis A virus and a norovirus surrogate in soft-shell clams (Mya arenaria). Appl Environ Microbiol. 2009;75(22):6992–2002.

19. Aguirre JS, Pin C, Rodriguez MR, Garcia de Fernando GD. Analysis of the encoded by the 5’-noncoding region and the E2 envelope glycoprotein.

20. Lever MS, Nelson M, Ireland PI, Stagg AJ, Beamish RJ, Hall GA, et al. Experimental aerogenic Burkholderia mallei (glanders) infection in the mouse. J Pharmacol Toxicol Methods. 2014;71C:13

21. Lever MS, Nelson M, Ireland PI, Stagg AJ, Beamish RJ, Hall GA, et al. Experimental aerogenic Burkholderia mallei (glanders) infection in the mouse. J Pharmacol Toxicol Methods. 2014;71C:13

22. Jackson SN, Wang HY, Woods AS. In situ structural characterization of glycerophospholipids and sulfatides in brain tissue using MALDI-MS/MS. J Am Soc Mass Spectrom. 2007;18(1):17–26.

23. Sparvero LJ, Amoscato AA, Dixon CE, Long JB, Kochanek PM, Pitt BR, et al. Mapping of phospholipids by MALDI imaging (MALDI-MSI): realities and expectations. Chem Phys Lipids. 2012;165(5):545–62.

24. Jackson SN, Barbacci D, Egan T, Lewis EK, Schulz JA, Woods AS. MALDI-Ion Mobility Mass Spectrometry of Lipids in Negative Ion Mode. Analytical methods : advancing methods and applications. 2014;6(14):5001–7.

25. Scholz B, Skold K, Kultima K, Fernandez C, Waldemarson S, Savitski MM, et al. Impact of temperature dependent sampling procedures in proteomics and peptidomics—a characterization of the liver and pancreas post mortem degradation. Molecular & cellular proteomics. MCP. 2011;10(3):M1100229-MP1-M1000229.

26. Bountree CB, Van Kirk CA, You H, Ding W, Dang H, VanGuilder HD, et al. Clinical application for the preservation of phospho-proteins through in-situ tissue stabilization. Proteome Sci. 2010;8:61.

27. Goodwin RJ, Nilsson A, Borg D, Langridge-Smith PR, Harrison DJ, Mackay CL, et al. Conductive carbon tape used for support and mounting of both whole animal and fragile heat-treated tissue sections for MALDI MSI imaging and quantitation. J Proteome Res. 2012;75(16):4912–20.

28. Goodwin RJ, Pennington SR, Pitt AR. Protein and peptides in pictures: imaging with MALDI mass spectrometry. Proteomics. 2008;8(18):3785–800.

29. Clavero MR, Beuchat LR, Doyle MP. Thermal inactivation of Escherichia coli O157:H7 isolated from ground beef and bovine feces, and suitability of media for enumeration. J Food Prot. 1998;61(3):285–9.

30. Thomas C, Swayne DE. Thermal inactivation of HSN1: high pathogenicity avian influenza virus in naturally infected chicken meat. J Food Prot. 2007;70(3):674–80.

31. Tuladhar E, Bouwknecht M, Zvietiering MH, Koopmans M, Duizer E. Thermal stability of structurally different viruses with proven or potential relevance to food safety. J Appl Microbiol. 2012;112(5):1050–7.

32. Baeit L, Wobus CE, Van Coillie E, Thackray LB, Debevere J, Uyttendaele M. Detection of murine norovirus 1 by using plaque assay, transfection assay, and real-time reverse transcription-PCR before and after heat exposure. Appl Environ Microbiol. 2008;74(2):543–6.

33. Anderson DM, Ablonczy Z, Koutalos Y, Spraggins J, Crouch RK, Caprioli RM, et al. High resolution MALDI imaging mass spectrometry of retinal tissue lipids. J Am Soc Mass Spectrom. 2014;25(8):1394–403.

34. Jones EE, Powers TW, Neely BA, Cazares LH, Troyer DA, Parker AS, et al. MALDI imaging mass spectrometry profiling of proteins and lipids in clear cell renal cell carcinoma. Proteomics. 2014;14(7–8):924–35.

35. Gode D, Volmer DA. Lipid imaging by mass spectrometry - a review. Analyst. 2013;138(5):1289–315.

36. Guo S, Qiu L, Wang Y, Qin X, Liu H, He M, et al. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal Bioanal Chem. 2014;406(18):3457–70.

37. Jermeren F, Söderquist M, Karlsson O. Post-sampling release of free fatty acids - effects of heat stabilization and methods of euthanasia. J Pharmacol Toxicol Methods. 2014;6(14):5001–20.

38. Patterson NH, Thomas A, Chaurand P, Monitoring time-dependent degradation of phospholipids in sectioned tissues by MALDI imaging mass spectrometry. J Pharmacol Toxicol Methods. 2014;71C:13

39. Sparvero LJ, Amoscato AA, Dixon CE, Long JB, Kochanek PM, Pitt BR, et al. Mapping of phospholipids by MALDI imaging (MALDI-MSI): realities and expectations. Chem Phys Lipids. 2012;165(5):545–62.

40. Jackson SN, Barbacci D, Egan T, Lewis EK, Schulz JA, Woods AS. MALDI-Ion Mobility Mass Spectrometry of Lipids in Negative Ion Mode. Analytical methods : advancing methods and applications. 2014;6(14):5001–7.